endpoints.news is our new home on June 1. endpts.com will still work, but the front door is now https://endpoints.news

Two pub­lic biotechs seek to merge, fo­cus­ing on desmoid tu­mors. But Nas­daq is not guar­an­teed

3 years ago
Deals
R&D

Biotech lay­offs con­tin­ue as Am­brx cuts staff and part of its pipeline to ex­tend its cash

3 years ago
People
R&D

Ever­est climbs clos­er to Covid-19 boost­er mar­ket; A French up­start snags funds to find drugs

3 years ago
News Briefing

Backed by Or­biMed, Sanofi vet's start­up tack­les the many mu­ta­tions of breast can­cer at once

3 years ago
Financing
R&D

Can a lit­tle start­up equipped with an Eli Lil­ly castoff make it big with an on­col­o­gy IPO? In 2022?

3 years ago
Financing
Deals

FDA com­mis­sion­er on ac­cel­er­at­ed ap­proval re­forms: 'Need to ad­dress as soon as pos­si­ble'

3 years ago
FDA+

No­var­tis-part­nered Ori­o­n­is se­cures $55M to push cy­tokine pro­gram in­to clin­ic

3 years ago
Financing

Up­dat­ed: Zymeworks want­ed a Big Phar­ma part­ner for its bis­pe­cif­ic. Jazz Phar­ma­ceu­ti­cals said OK

3 years ago
Deals
Pharma

Up­dat­ed: In new speed bump for Hunt­ing­ton's, FDA paus­es PTC's PhII tri­al

3 years ago
R&D
FDA+

Drug dis­cov­ery biotech look­ing in­to the ‘dark’ re­gions of the hu­man genome picks up a $40M+ Se­ries A

3 years ago
Financing
Startups

Scoop: Af­ter hep B set­back, an Or­biMed-backed NASH biotech hunts for part­ners as it rais­es Se­ries C

3 years ago
Financing
Startups

Tis­sue-ag­nos­tic drug de­vel­op­ment: FDA on­col­o­gy cen­ter of­fers draft guid­ance

3 years ago
FDA+

UK reg­u­la­tor se­lects tiny Mass­a­chu­setts biotech's po­ten­tial Gauch­er gene ther­a­py for ac­cel­er­at­ed path­way

3 years ago
Cell/Gene Tx

J&J holds off on volatile M&A mar­ket but has plen­ty of cash for a deal

3 years ago
R&D
Pharma

Roche CEO: As­sume 'sharp de­cline' in Covid-re­lat­ed sales next year

3 years ago
Pharma

Ex­clu­sive: Strug­gling Ed­i­tas shops pre­clin­i­cal can­cer pipeline dur­ing its big makeover

3 years ago
Deals

Big Phar­ma PACs blan­ket the elec­tion field with mil­lions in con­tri­bu­tions ahead of midterms

3 years ago
Law

Dis­ease aware­ness daze: Do pa­tients and peo­ple tune out health con­di­tion months and re­lat­ed mar­ket­ing?

3 years ago
Pharma
Marketing

Mar­ket­ingRx roundup: No­var­tis spot­lights breast can­cer pa­tient sto­ries; Cal­i­for­nia al­lots $40M for opi­oid ad cam­paign

3 years ago
Pharma
Marketing

Backed by Bob Langer, for­mer Har­vard prof sets out to test a new way to de­liv­er I/O drugs — dur­ing surgery

3 years ago
Financing
Startups

Where CAR-Ts were in 2012? For­mer Tmu­ni­ty CEO Oz Azam un­veils not-quite-a-psy­che­delics biotech

3 years ago
R&D

Pfiz­er nabs eq­ui­ty stake in Swiss biotech work­ing on celi­ac ther­a­py; Verona gets more cash af­ter COPD win

3 years ago
News Briefing

Roche cuts PhII eye dis­ease pro­gram, one day af­ter an­oth­er biotech flopped in same in­di­ca­tion

3 years ago
R&D

Hous­ton start­up paus­es en­roll­ment in pe­di­atric can­cer tri­al af­ter pa­tient death

3 years ago
R&D
First page Previous page 442443444445446447448 Next page Last page
A service from the Financial Times